Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD

January 18, 2024 updated by: John Hart, Jr., The University of Texas at Dallas
The purpose of this study is to examine the benefits of combining repetitive Transcranial Magnetic Stimulation (rTMS) coupled with Cognitive Processing Therapy (CPT) in treating combat-related Posttraumatic Stress Disorder (PTSD) symptoms. The study will also examine change in depression, psychosocial functioning, and neurophysiological (i.e., electroencephalography and magnetic resonance images) measures.

Study Overview

Detailed Description

Using three treatment arms, the study will examine Posttraumatic Stress Disorder (PTSD) symptom reduction when (1) 1 Hz (hertz) repetitive transcranial magnetic stimulation (rTMS) to the right dorsolateral prefrontal cortex (rDLPFC) is administered prior to each of 12 Cognitive Processing Therapy (CPT) sessions compared to when (2) sham rTMS is administered to the rDLPFC is administered prior to each of 12 CPT sessions and to when (3) 1 Hz rTMS is delivered to rDLPFC alone over 12 sessions.

Veterans with combat-related PTSD will be randomly assigned to one of the three treatment arms. Primary outcome PTSD symptom severity measures, secondary neuropsychological, electroencephalography (EEG), and magnetic resonance imaging (MRI) outcome measures, and prescreening assessments for study contraindicators will be collected prior to being assigned to a treatment arm (i.e., baseline).

Primary outcome PTSD symptom severity measures and secondary neuropsychological outcome measures will be collected twice within the span of the treatment sessions (i.e., sessions 5 and 9) and at three times following treatment competition (i.e., 1-month, 6-months, and 12-months). EEG also will be collected at the 1-month, 6-month, and 12-month assessments, and MRI will be collected at the 6-month and 12-month assessments.

Study Type

Interventional

Enrollment (Estimated)

330

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Florida
      • Tallahassee, Florida, United States, 32308
        • Recruiting
        • Florida State University College of Medicine
        • Contact:
    • Texas
      • Addison, Texas, United States, 75001
        • Recruiting
        • Metrocare Services of Dallas
        • Contact:
      • Dallas, Texas, United States, 75235
        • Recruiting
        • The University of Texas at Dallas
        • Sub-Investigator:
          • Michael Motes, PhD
        • Sub-Investigator:
          • Gail Tillman, PhD
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Veterans of Post-9/11 military conflicts
  • with diagnosis of PTSD based on CAPS-5 related to Post-9/11 military combat

Exclusion Criteria:

  • current enrollment in an acute experimental treatment for PTSD or trauma-focused psychotherapy treatment
  • PTSD-inducing trauma exposure occurring within the last 3 months prior to pre-enrollment evaluation
  • history of epilepsy or seizure disorder, a history of major head trauma,
  • any neurologic condition likely to increase risk of seizures,
  • brain tumors,
  • moderate to severe substance use disorder in last 3 months or any substance use that puts the participant at increased risk or significant impairment
  • stroke, and blood vessel abnormalities in the brain,
  • dementia,
  • Parkinson's disease, Huntington's chorea, or multiple sclerosis
  • a high suicide risk
  • a lifetime history of psychotic disorder or bipolar disorder
  • inability to stop taking any medication that significantly lowers the seizure threshold
  • pregnant or nursing
  • metal fragments in the head, or any metal objects in or near the head that cannot be safely removed
  • We will screen for a history of traumatic brain injury and exclude potential participants from the study if they have a history of severe TBI or are at high risk for seizures.
  • history of seizures
  • non-English speakers because not all of the screening forms, questionnaires, and tests are available in any language except for English
  • cardiac pacemaker, implanted medication pumps of any sort that would increase the risk of rTMS
  • any current medical condition that could preclude being able to safely participate in TMS treatment,
  • use of prescription medication or illegal substances that lower the seizure threshold
  • previous rTMS

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Sham rTMS + CPT
30 minutes of sham repetitive transcranial magnetic stimulation (rTMS) to the right dorsolateral prefrontal cortex (rDLPFC) prior to each Cognitive Processing Therapy (CPT) session

A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be used to deliver 1 hertz (Hz) stimulation to right dorsolateral prefrontal cortex (rDLPFC) at 110% of a participant's rTMS motor threshold. The device passes electric current through a coil generating an alternating magnetic field. When positioned over the skull, the changing magnetic field causes electromagnetic inducted current flow in brain regions subjacent to the coil. Magnetic pulses (1.5-2.0 Tesla) lasting 100-300 microseconds at 1 Hz will be used.

Motor threshold will be defined by the TMS intensity to right motor region required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time.

Other Names:
  • 1 Hz repetitive transcranial magnetic stimulation
Cognitive Processing Therapy (CPT) is an evidenced based, trauma-focused treatment for Posttraumatic Stress Disorder (PTSD). CPT is a recommended form of treatment in the Veterans Administration - Department of Defense Clinical Practice Guideline for PTSD. The CPT manual delineates the agenda for each of 12 sessions (60 minutes per session): 1) Introduction to CPT and Patient Education regarding PTSD, 2) Meaning of the Trauma, 3) Identification of Thoughts and Feelings related to the Trauma, 4) Remembering the Trauma, 5) Identification of Stuck points, 6) Challenging Questions about the Trauma, 7) Dysfunctional/Maladaptive Thinking patterns related to the Trauma, 8) Safety Issues, 9) Trust Issues, 10) Power and Control Issues, 11) Self-Esteem Issues, and 12) Intimacy Issues.
Other Names:
  • CPT
Active Comparator: Active rTMS + CPT
30 minutes of 1 Hz rTMS to rDLPFC prior to each CPT session
Cognitive Processing Therapy (CPT) is an evidenced based, trauma-focused treatment for Posttraumatic Stress Disorder (PTSD). CPT is a recommended form of treatment in the Veterans Administration - Department of Defense Clinical Practice Guideline for PTSD. The CPT manual delineates the agenda for each of 12 sessions (60 minutes per session): 1) Introduction to CPT and Patient Education regarding PTSD, 2) Meaning of the Trauma, 3) Identification of Thoughts and Feelings related to the Trauma, 4) Remembering the Trauma, 5) Identification of Stuck points, 6) Challenging Questions about the Trauma, 7) Dysfunctional/Maladaptive Thinking patterns related to the Trauma, 8) Safety Issues, 9) Trust Issues, 10) Power and Control Issues, 11) Self-Esteem Issues, and 12) Intimacy Issues.
Other Names:
  • CPT

A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be paired with sham coil. The sham coil will induce electrical current flow in the tissue above the skull but will not induce current flow in brain tissue. The sham coil will be placed over the right prefrontal scalp region to target current flow in rDLPFC. Magnetic pulses lasting for 100-300 microseconds at 1 Hz will be used.

For consistency across the rTMS conditions, motor threshold in the sham condition also will be determined by positioning the active rTMS coil over the right motor region and identifying the stimulation intensity required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time.

Other Names:
  • sham repetitive transcranial magnetic stimulation
Active Comparator: Active rTMS Alone
30 minutes of 1 Hz rTMS to rDLPFC at 1 session per week over 12 weeks

A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be used to deliver 1 hertz (Hz) stimulation to right dorsolateral prefrontal cortex (rDLPFC) at 110% of a participant's rTMS motor threshold. The device passes electric current through a coil generating an alternating magnetic field. When positioned over the skull, the changing magnetic field causes electromagnetic inducted current flow in brain regions subjacent to the coil. Magnetic pulses (1.5-2.0 Tesla) lasting 100-300 microseconds at 1 Hz will be used.

Motor threshold will be defined by the TMS intensity to right motor region required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time.

Other Names:
  • 1 Hz repetitive transcranial magnetic stimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment group differences in change from baseline to 6-months post-treatment on the Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Total Severity Score
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences on the Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Total Severity Score (20 item sum, range 0-80, higher score=greater severity) in change from baseline to 6 months after the 12-week interventions.

Weathers, FW, Blake, DD, Schnurr, PP, Kaloupek, DG, Marx, BP, & Keane, TM. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). www.ptsd.va.gov: National Center for PTSD, 2013.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment group differences in change from baseline to 1 month post-treatment on the Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Total Severity Score
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences on the Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Total Severity Score (20 item sum, range 0-80, higher score=greater severity) in change from baseline to 1 month after the 12-week interventions.

Weathers, FW, Blake, DD, Schnurr, PP, Kaloupek, DG, Marx, BP, & Keane, TM. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). www.ptsd.va.gov: National Center for PTSD, 2013.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment on the Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Total Severity Score
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences on the Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Total Severity Score (20 item sum, range 0-80, higher score=greater severity) in change from baseline to 12 months after the 12-week interventions.

Weathers, FW, Blake, DD, Schnurr, PP, Kaloupek, DG, Marx, BP, & Keane, TM. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). www.ptsd.va.gov: National Center for PTSD, 2013.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 1 month post-treatment on the Posttraumatic Stress Disorder Checklist for for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Total Severity Score
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences on the Posttraumatic Stress Disorder Checklist for for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Total Severity Score (20 item sum, range 0-80, higher score=greater severity) in change from baseline to 1 month after the 12-week interventions.

Weathers FW, Litz BT, Keane TM, Palmieri PA, Marx BP, Schnurr PP. The PTSD Checklist for DSM-5 (PCL-5). Scale available from the National Center for PTSD at www.ptsd.va.gov, 2013.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment on the Posttraumatic Stress Disorder Checklist for for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Total Severity Score
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences on the Posttraumatic Stress Disorder Checklist for for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Total Severity Score (20 item sum, range 0-80, higher score=greater severity) in change from baseline to 6 months after the 12-week interventions.

Weathers FW, Litz BT, Keane TM, Palmieri PA, Marx BP, Schnurr PP. The PTSD Checklist for DSM-5 (PCL-5). Scale available from the National Center for PTSD at www.ptsd.va.gov, 2013.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment on the Posttraumatic Stress Disorder Checklist for for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Total Severity Score
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences on the Posttraumatic Stress Disorder Checklist for for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Total Severity Score (20 item sum, range 0-80, higher score=greater severity) in change from baseline to 12 months after the 12-week interventions.

Weathers FW, Litz BT, Keane TM, Palmieri PA, Marx BP, Schnurr PP. The PTSD Checklist for DSM-5 (PCL-5). Scale available from the National Center for PTSD at www.ptsd.va.gov, 2013.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 1 month post-treatment on the Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Symptom Cluster Scores
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences on Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Symptom Cluster Scores (cluster item sum, higher scores=greater severity) in change from baseline to 1 month after the 12-week interventions. Evaluations of 4-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Cognition/Mood, range 0-28, and [4] Arousal/Reactivity, range 0-24) and 7-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Affect, range 0-16), [4] Anhedonia, range 0-12, [5] Externalizing, range 0-8, [6] Anxious Arousal, range 0-8, and [7] Dysphoric Arousal, range 0-8).

Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, Keane TM, Marx BP. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess 30(3):383-395, 2018.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment on the Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Symptom Cluster Scores
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences on Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Symptom Cluster Scores (cluster item sum, higher scores=greater severity) in change from baseline to 6 months after the 12-week interventions. Evaluations of 4-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Cognition/Mood, range 0-28, and [4] Arousal/Reactivity, range 0-24) and 7-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Affect, range 0-16), [4] Anhedonia, range 0-12, [5] Externalizing, range 0-8, [6] Anxious Arousal, range 0-8, and [7] Dysphoric Arousal, range 0-8).

Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, Keane TM, Marx BP. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess 30(3):383-395, 2018.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment on the Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Symptom Cluster Scores
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences on Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Symptom Cluster Scores (cluster item sum, higher scores=greater severity) in change from baseline to 12 months after the 12-week intervention. Evaluations of 4-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Cognition/Mood, range 0-28, and [4] Arousal/Reactivity, range 0-24) and 7-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Affect, range 0-16), [4] Anhedonia, range 0-12, [5] Externalizing, range 0-8, [6] Anxious Arousal, range 0-8, and [7] Dysphoric Arousal, range 0-8).

Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, Keane TM, Marx BP. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess 30(3):383-395, 2018.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 6 weeks (5th intervention session) on the Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Total Score
Time Frame: Outcome measures will be measured twice over a period of 6 weeks: Baseline, 6 weeks

Evaluation of treatment group differences on the Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Total Severity Score (20 item sum, range 0-80, higher score=greater severity) in change from baseline to 6 weeks.

Weathers, F.W., Blake, D.D., Schnurr, P.P., Kaloupek, D.G., Marx, B.P., & Keane, T.M. (2013). The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). Interview available from the National Center for PTSD at www.ptsd.va.gov.

Outcome measures will be measured twice over a period of 6 weeks: Baseline, 6 weeks
Treatment group differences in change from baseline to 10 weeks (9th intervention session) on the Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Total Score
Time Frame: Outcome measures will be measured twice over a period of 10 weeks: Baseline, 10 weeks

Evaluation of treatment group differences on the Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Total Severity Score (20 item sum, range 0-80, higher score=greater severity) in change from baseline to 10 weeks.

Weathers, F.W., Blake, D.D., Schnurr, P.P., Kaloupek, D.G., Marx, B.P., & Keane, T.M. (2013). The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). Interview available from the National Center for PTSD at www.ptsd.va.gov.

Outcome measures will be measured twice over a period of 10 weeks: Baseline, 10 weeks
Treatment group differences in change from baseline to 6 weeks (5th intervention session) on the Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Symptom Cluster
Time Frame: Outcome measures will be measured twice over a period of 6 weeks: Baseline, 6 weeks

Evaluation of treatment group differences on Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Symptom Cluster Scores (cluster item sum, higher scores=greater severity) in change from baseline to 6 weeks. Evaluations of 4-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Cognition/Mood, range 0-28, and [4] Arousal/Reactivity, range 0-24) and 7-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Affect, range 0-16), [4] Anhedonia, range 0-12, [5] Externalizing, range 0-8, [6] Anxious Arousal, range 0-8, and [7] Dysphoric Arousal, range 0-8).

Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, Keane TM, Marx BP. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess 30(3):383-395, 2018.

Outcome measures will be measured twice over a period of 6 weeks: Baseline, 6 weeks
Treatment group differences in change from baseline to 10 weeks (9th intervention session) on the Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Symptom Clust
Time Frame: Outcome measures will be measured twice over a period of 10 weeks: Baseline, 10 weeks

Evaluation of treatment group differences on Clinician Administered Posttraumatic Stress Disorder Scale for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (CAPS-5) Symptom Cluster Scores (cluster item sum, higher scores=greater severity) in change from baseline to 10 weeks. Evaluations of 4-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Cognition/Mood, range 0-28, and [4] Arousal/Reactivity, range 0-24) and 7-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Affect, range 0-16), [4] Anhedonia, range 0-12, [5] Externalizing, range 0-8, [6] Anxious Arousal, range 0-8, and [7] Dysphoric Arousal, range 0-8).

Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, Keane TM, Marx BP. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess 30(3):383-395, 2018.

Outcome measures will be measured twice over a period of 10 weeks: Baseline, 10 weeks
Treatment group differences in change from baseline to 1 month post-treatment on the Posttraumatic Stress Disorder Checklist for for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Symptom Cluster Scores
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences on Posttraumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Symptom Cluster Scores (cluster item sum, higher scores=greater severity) in change from baseline to 1 month after 12-week interventions. Evaluations of 4-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Cognition/Mood, range 0-28, and [4] Arousal/Reactivity, range 0-24) and 7-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Affect, range 0-16), [4] Anhedonia, range 0-12, [5] Externalizing, range 0-8, [6] Anxious Arousal, range 0-8, and [7] Dysphoric Arousal, range 0-8).

Bovin, MJ, Marx, BP, Weathers, FW, Gallagher, MW, Rodriguez, P, Schnurr, PP, Keane, TM. Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in Veterans. Psychol Assess 28(11):1379-1391, 2016.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment on the Posttraumatic Stress Disorder Checklist for for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Symptom Cluster Scores
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences on Posttraumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Symptom Cluster Scores (cluster item sum, higher scores=greater severity) in change from baseline to 6 months after 12-week interventions. Evaluations of 4-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Cognition/Mood, range 0-28, and [4] Arousal/Reactivity, range 0-24) and 7-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Affect, range 0-16), [4] Anhedonia, range 0-12, [5] Externalizing, range 0-8, [6] Anxious Arousal, range 0-8, and [7] Dysphoric Arousal, range 0-8).

Bovin, MJ, Marx, BP, Weathers, FW, Gallagher, MW, Rodriguez, P, Schnurr, PP, Keane, TM. Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in Veterans. Psychol Assess 28(11):1379-1391, 2016.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment on the Posttraumatic Stress Disorder Checklist for for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Symptom Cluster Scores
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences on Posttraumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Symptom Cluster Scores (cluster item sum, higher scores=greater severity) in change from baseline to 12 months after 12-week interventions. Evaluations of 4-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Cognition/Mood, range 0-28, and [4] Arousal/Reactivity, range 0-24) and 7-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Affect, range 0-16), [4] Anhedonia, range 0-12, [5] Externalizing, range 0-8, [6] Anxious Arousal, range 0-8, and [7] Dysphoric Arousal, range 0-8).

Bovin, MJ, Marx, BP, Weathers, FW, Gallagher, MW, Rodriguez, P, Schnurr, PP, Keane, TM. Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in Veterans. Psychol Assess 28(11):1379-1391, 2016.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 6 weeks (5th intervention session) on the Posttraumatic Stress Disorder Checklist for for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Symptom Cluster Scores
Time Frame: Outcome measures will be measured twice over a period of 6 weeks: Baseline, 6 weeks

Evaluation of treatment group differences on Posttraumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Symptom Cluster Scores (cluster item sum, higher scores=greater severity) in change from baseline to 6 weeks. Evaluations of 4-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Cognition/Mood, range 0-28, and [4] Arousal/Reactivity, range 0-24) and 7-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Affect, range 0-16), [4] Anhedonia, range 0-12, [5] Externalizing, range 0-8, [6] Anxious Arousal, range 0-8, and [7] Dysphoric Arousal, range 0-8).

Bovin, MJ, Marx, BP, Weathers, FW, Gallagher, MW, Rodriguez, P, Schnurr, PP, Keane, TM. Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in Veterans. Psychol Assess 28(11):1379-1391, 2016.

Outcome measures will be measured twice over a period of 6 weeks: Baseline, 6 weeks
Treatment group differences in change from baseline to 10 weeks (9th intervention session) on the Posttraumatic Stress Disorder Checklist for for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Symptom Cluster Scores
Time Frame: Outcome measures will be measured twice over a period of 10 weeks: Baseline, 10 weeks

Evaluation of treatment group differences on Posttraumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders (5th edition) (PCL-5) Symptom Cluster Scores (cluster item sum, higher scores=greater severity) in change from baseline to 10 weeks. Evaluations of 4-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Cognition/Mood, range 0-28, and [4] Arousal/Reactivity, range 0-24) and 7-Symptom Cluster Model ([1] Intrusions, range 0-20, [2] Avoidance, range 0-8, [3] Negative Affect, range 0-16), [4] Anhedonia, range 0-12, [5] Externalizing, range 0-8, [6] Anxious Arousal, range 0-8, and [7] Dysphoric Arousal, range 0-8).

Bovin, MJ, Marx, BP, Weathers, FW, Gallagher, MW, Rodriguez, P, Schnurr, PP, Keane, TM. Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in Veterans. Psychol Assess 28(11):1379-1391, 2016.

Outcome measures will be measured twice over a period of 10 weeks: Baseline, 10 weeks
Treatment group differences in change from baseline to 1 month post-treatment on the Mississippi Scale for Combat Related Posttraumatic Stress Disorder
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences on the Mississippi Scale for Combat Related Posttraumatic Stress Disorder Total Score (35 item sum, range 35-175, higher score=greater severity) in change from baseline to 1-month after the 12-week interventions.

Keane TM, Caddell JM, Taylor KL. Mississippi Scale for Combat-Related Posttraumatic Stress Disorder: three studies in reliability and validity. J Consult Clin Psychol 56(1):85-90, 1988.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment on the Mississippi Scale for Combat Related Posttraumatic Stress Disorder
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences on the Mississippi Scale for Combat Related Posttraumatic Stress Disorder Total Score (35 item sum, range 35-175, higher score=greater severity) in change from baseline to 6-months after the 12-week interventions.

Keane TM, Caddell JM, Taylor KL. Mississippi Scale for Combat-Related Posttraumatic Stress Disorder: three studies in reliability and validity. J Consult Clin Psychol 56(1):85-90, 1988.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment on the Mississippi Scale for Combat Related Posttraumatic Stress Disorder
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences on the Mississippi Scale for Combat Related Posttraumatic Stress Disorder Total Score (35 item sum, range 35-175, higher score=greater severity) in change from baseline to 12-months after the 12-week interventions.

Keane TM, Caddell JM, Taylor KL. Mississippi Scale for Combat-Related Posttraumatic Stress Disorder: three studies in reliability and validity. J Consult Clin Psychol 56(1):85-90, 1988.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 1 month post-treatment on Montgomery Asberg Depression Rating Scale
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences on the Montgomery Asberg Depression Rating Scale (10 item sum, range 0-60, higher score=greater severity) in change from baseline to 1-month after the 12-week interventions.

Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389, 1979.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment on Montgomery Asberg Depression Rating Scale
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences on the Montgomery Asberg Depression Rating Scale (10 item sum, range 0-60, higher score=greater severity) in change from baseline to 6-months after the 12-week interventions.

Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389, 1979.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment on Montgomery Asberg Depression Rating Scale
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences on the Montgomery Asberg Depression Rating Scale (10 item sum, range 0-60, higher score=greater severity) in change from baseline to 12-months after the 12-week interventions.

Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389, 1979.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 6 weeks (5th intervention session) on Montgomery Asberg Depression Rating Scale
Time Frame: Outcome measures will be measured twice over a period of 6 weeks: Baseline, 6 weeks

Evaluation of treatment group differences on the Montgomery Asberg Depression Rating Scale (10 item sum, range 0-60, higher score=greater severity) in change from baseline to 6 weeks.

Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389, 1979.

Outcome measures will be measured twice over a period of 6 weeks: Baseline, 6 weeks
Treatment group differences in change from baseline to 10 weeks (9th intervention session) on Montgomery Asberg Depression Rating Scale
Time Frame: Outcome measures will be measured twice over a period of 10 weeks: Baseline, 10 weeks

Evaluation of treatment group differences on the Montgomery Asberg Depression Rating Scale (10 item sum, range 0-60, higher score=greater severity) in change from baseline to 10 weeks.

Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389, 1979.

Outcome measures will be measured twice over a period of 10 weeks: Baseline, 10 weeks
Treatment group differences in change from baseline to 1 month post-treatment on the Quick Inventory of Depressive Symptomatology
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences on the Quick Inventory of Depressive Symptomatology (QIDS) (9 domain sum, range 0-27, higher score=greater severity) in change from baseline to 1-month after the 12-week interventions.

Rush, AJ, Trivedi, MH, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54(5):573-583, 2003.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment on the Quick Inventory of Depressive Symptomatology
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences on the Quick Inventory of Depressive Symptomatology (QIDS) (9 domain sum, range 0-27, higher score=greater severity) in change from baseline to 6-months after the 12-week interventions.

Rush, AJ, Trivedi, MH, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54(5):573-583, 2003.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment on the Quick Inventory of Depressive Symptomatology
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences on the Quick Inventory of Depressive Symptomatology (QIDS) (9 domain sum, range 0-27, higher score=greater severity) in change from baseline to 12-months after the 12-week interventions.

Rush, AJ, Trivedi, MH, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54(5):573-583, 2003.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 6 weeks (5th intervention session ) on the Quick Inventory of Depressive Symptomatology
Time Frame: Outcome measures will be measured twice over a period of 6 weeks: Baseline, 6 weeks

Evaluation of treatment group differences on the Quick Inventory of Depressive Symptomatology (QIDS) (9 domain sum, range 0-27, higher score=greater severity) in change from baseline to 6 weeks.

Rush, AJ, Trivedi, MH, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54(5):573-583, 2003.

Outcome measures will be measured twice over a period of 6 weeks: Baseline, 6 weeks
Treatment group differences from baseline to 10 weeks (9th intervention session) on the Quick Inventory of Depressive Symptomatology
Time Frame: Outcome measures will be measured twice over a period of 10 weeks: Baseline, 10 weeks

Evaluation of treatment group differences on the Quick Inventory of Depressive Symptomatology (QIDS) (9 domain sum, range 0-27, higher score=greater severity) in change from baseline to 10 weeks.

Rush, AJ, Trivedi, MH, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54(5):573-583, 2003.

Outcome measures will be measured twice over a period of 10 weeks: Baseline, 10 weeks
Treatment group differences in change from baseline to 1 month post-treatment on the Inventory of Psychosocial Functioning
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences on the Inventory of Psychosocial Functioning (IPF) Overall Score (mean of completed domain scores, range 0-100, higher score=greater impairment) in change from baseline to 1 month following the 12-week interventions.

Bovin MJ, Black SK, Rodriguez P, Lunney CA, Kleiman SE, Weathers FW, Schnurr PP, Spira J, Keane TM, Marx BP. Development and validation of a measure of PTSD-related psychosocial functional impairment: The Inventory of Psychosocial Functioning. Psychol Serv 15(2):216-229, 2018.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment on the Inventory of Psychosocial Functioning
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences on the Inventory of Psychosocial Functioning (IPF) Overall Score (mean of completed domain scores, range 0-100, higher score=greater impairment) in change from baseline to 6 months after the 12-week interventions.

Bovin MJ, Black SK, Rodriguez P, Lunney CA, Kleiman SE, Weathers FW, Schnurr PP, Spira J, Keane TM, Marx BP. Development and validation of a measure of PTSD-related psychosocial functional impairment: The Inventory of Psychosocial Functioning. Psychol Serv 15(2):216-229, 2018.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment on the Inventory of Psychosocial Functioning
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences on the Inventory of Psychosocial Functioning (IPF) Overall Score (mean of completed domain scores, range 0-100, higher score=greater impairment) in change from baseline to 12 months after the 12-week interventions.

Bovin MJ, Black SK, Rodriguez P, Lunney CA, Kleiman SE, Weathers FW, Schnurr PP, Spira J, Keane TM, Marx BP. Development and validation of a measure of PTSD-related psychosocial functional impairment: The Inventory of Psychosocial Functioning. Psychol Serv 15(2):216-229, 2018.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 1 month post-treatment on the Short Impulsive Behavior Scale
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences on the Short Impulsive Behavior Scale (UPPS-P) Total Score (mean item rating, range 1-4, higher score=greater impulsivity) in change from baseline to 1 month after the 12-week interventions.

Cyders MA, Littlefield AK, Coffey S, Karyadi KA. Examination of a short English version of the UPPS-P Impulsive Behavior Scale. Addict Behav 39(9):1372-1376, 2014.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment on the Short Impulsive Behavior Scale
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences on the Short Impulsive Behavior Scale (UPPS-P) Total Score (mean item rating, range 1-4, higher score=greater impulsivity) in change from baseline to 6 months after the 12-week interventions.

Cyders MA, Littlefield AK, Coffey S, Karyadi KA. Examination of a short English version of the UPPS-P Impulsive Behavior Scale. Addict Behav 39(9):1372-1376, 2014.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment on the Short Impulsive Behavior Scale
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences on the Short Impulsive Behavior Scale (UPPS-P) Total Score (mean item rating, range 1-4, higher score=greater impulsivity) in change from baseline to 12 months after the 12-week interventions.

Cyders MA, Littlefield AK, Coffey S, Karyadi KA. Examination of a short English version of the UPPS-P Impulsive Behavior Scale. Addict Behav 39(9):1372-1376, 2014.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 1 month post-treatment on the Short Impulsive Behavior Subscales
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences on the Short Impulsive Behavior Scale (UPPS-P) Subscale Scores (mean item rating, range 1-4, higher score=greater impulsivity) in change from baseline to 1 month after the 12-week interventions. Evaluations on (1) Negative Urgency, (2) Perseverance, (3) Premeditation, (4) Sensation Seeking, and (5) Positive Urgency

Cyders MA, Littlefield AK, Coffey S, Karyadi KA. Examination of a short English version of the UPPS-P Impulsive Behavior Scale. Addict Behav 39(9):1372-1376, 2014.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment on the Short Impulsive Behavior Subscales
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences on the Short Impulsive Behavior Scale (UPPS-P) Subscale Scores (mean item rating, range 1-4, higher score=greater impulsivity) in change from baseline to 6 months after the 12-week interventions. Evaluations on (1) Negative Urgency, (2) Perseverance, (3) Premeditation, (4) Sensation Seeking, and (5) Positive Urgency

Cyders MA, Littlefield AK, Coffey S, Karyadi KA. Examination of a short English version of the UPPS-P Impulsive Behavior Scale. Addict Behav 39(9):1372-1376, 2014.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment on the Short Impulsive Behavior Subscales
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences on the Short Impulsive Behavior Scale (UPPS-P) Subscale Scores (mean item rating, range 1-4, higher score=greater impulsivity) in change from baseline to 12 months after the 12-week interventions. Evaluations on (1) Negative Urgency, (2) Perseverance, (3) Premeditation, (4) Sensation Seeking, and (5) Positive Urgency

Cyders MA, Littlefield AK, Coffey S, Karyadi KA. Examination of a short English version of the UPPS-P Impulsive Behavior Scale. Addict Behav 39(9):1372-1376, 2014.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change in aggression from baseline to 1 month post-treatment on the Buss-Perry Aggression Questionnaire
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences on the Buss-Perry Aggression Questionnaire Total Score (29 item sum, range 29-145, higher score=greater aggression) in change from baseline to 1 month after the 12-week interventions.

Buss AH, Perry M. The Aggression Questionnaire. J Pers Soc Psychol 63(3):452-459, 1992.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment on the Buss-Perry Aggression Questionnaire
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences on the Buss-Perry Aggression Questionnaire Total Score (29 item sum, range 29-145, higher score=greater aggression) in change from baseline to 6 months after the 12-week interventions.

Buss AH, Perry M. The Aggression Questionnaire. J Pers Soc Psychol 63(3):452-459, 1992.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment on the Buss-Perry Aggression Questionnaire
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences on the Buss-Perry Aggression Questionnaire Total Score (29 item sum, range 29-145, higher score=greater aggression) in change from baseline to 12 months after the 12-week interventions.

Buss AH, Perry M. The Aggression Questionnaire. J Pers Soc Psychol 63(3):452-459, 1992.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 1 month post-treatment on the Buss-Perry Aggression Questionnaire Subscales
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences on the Buss-Perry Aggression Questionnaire Subscale Scores (subscale item sum, higher score=greater aggression) in change from baseline to 1 month after the 12-week interventions. Evaluated on: Physical Aggression (9 items, range 9-45), Verbal Aggression (5 items, range 5-25), Anger (7 items, range 7-35), and Hostility (8 items, range 8-40).

Buss AH, Perry M. The Aggression Questionnaire. J Pers Soc Psychol 63(3):452-459, 1992.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment on the Buss-Perry Aggression Questionnaire Subscales
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences on the Buss-Perry Aggression Questionnaire Subscale Scores (subscale item sum, higher score=greater aggression) in change from baseline to 6 months after the 12-week interventions. Evaluated on: Physical Aggression (9 items, range 9-45), Verbal Aggression (5 items, range 5-25), Anger (7 items, range 7-35), and Hostility (8 items, range 8-40).

Buss AH, Perry M. The Aggression Questionnaire. J Pers Soc Psychol 63(3):452-459, 1992.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment on the Buss-Perry Aggression Questionnaire Subscales
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences on the Buss-Perry Aggression Questionnaire Subscale Scores (subscale item sum, higher score=greater aggression) in change from baseline to 12 months after the 12-week interventions. Evaluated on: Physical Aggression (9 items, range 9-45), Verbal Aggression (5 items, range 5-25), Anger (7 items, range 7-35), and Hostility (8 items, range 8-40).

Buss AH, Perry M. The Aggression Questionnaire. J Pers Soc Psychol 63(3):452-459, 1992.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 1 month post-treatment in event-related potential in response to trauma-specific auditory stimuli
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences in change from baseline to 1 month following the 12-week interventions in event-related potential (ERP) on trauma-specific threatening auditory stimuli compared to non-specific threatening and non-threatening auditory stimuli. Measured as change in microvolts separately on the N2 and P3 ERP components.

Tillman GD et al. Repetitive transcranial magnetic stimulation and threat memory: selective reduction of combat threat memory p300 response after right frontal-lobe stimulation. J Neuropsychiatry Clin Neurosci 23(1):40-7, 2011.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment in event-related potential in response to trauma-specific auditory stimuli
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences in change from baseline to 6 months following the 12-week interventions in event-related potential (ERP) on trauma-specific threatening auditory stimuli compared to non-specific threatening and non-threatening auditory stimuli. Measured as change in microvolts separately on the N2 and P3 ERP components.

Tillman GD et al. Repetitive transcranial magnetic stimulation and threat memory: selective reduction of combat threat memory p300 response after right frontal-lobe stimulation. J Neuropsychiatry Clin Neurosci 23(1):40-7, 2011.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment in event-related potential in response to trauma-specific auditory stimuli
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences in change from baseline to 12 months following the 12-week interventions in event-related potential (ERP) on trauma-specific threatening auditory stimuli compared to non-specific threatening and non-threatening auditory stimuli. Measured as change in microvolts separately on the N2 and P3 ERP components.

Tillman GD et al. Repetitive transcranial magnetic stimulation and threat memory: selective reduction of combat threat memory p300 response after right frontal-lobe stimulation. J Neuropsychiatry Clin Neurosci 23(1):40-7, 2011.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 1 month post-treatment in event-related potential in response to trauma-specific visual stimuli
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences in change from baseline to 1 month following the 12-week interventions in event-related potential (ERP) on trauma-specific visual stimuli compared to non-specific threatening and non-threatening visual stimuli. Measured as change in microvolts separately on the N2 and P3 ERP components.

DeLaRosa BL et al. Electrophysiological spatiotemporal dynamics during implicit visual threat processing. Brain Cogn 91:54-61, 2014.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment in event-related potential in response to trauma-specific visual stimuli
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences in change from baseline to 6 months following the 12-week interventions in event-related potential (ERP) on trauma-specific visual stimuli compared to non-specific threatening and non-threatening visual stimuli. Measured as change in microvolts separately on the N2 and P3 ERP components.

DeLaRosa BL et al. Electrophysiological spatiotemporal dynamics during implicit visual threat processing. Brain Cogn 91:54-61, 2014.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment in event-related potential in response to trauma-specific visual stimuli
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences in change from baseline to 12 months following the 12-week interventions in event-related potential (ERP) on trauma-specific visual stimuli compared to non-specific threatening and non-threatening visual stimuli. Measured as change in microvolts separately on the N2 and P3 ERP components.

DeLaRosa BL et al. Electrophysiological spatiotemporal dynamics during implicit visual threat processing. Brain Cogn 91:54-61, 2014.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 1 month post-treatment in electroencephalography power in response to trauma-specific auditory stimuli
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences in change from baseline to 1 month following the 12-week interventions in change in electroencephalography (EEG) power within alpha- and theta-bands to trauma-specific threatening auditory stimuli compared to non-specific threatening and non-threatening auditory stimuli. For task conditions of interest, EEG power will be calculated separately at each electrode as log transformed, absolute power averages in the delta (1.5-3.5 Hz), theta (4-7.5 Hz), alpha (8-13 Hz), and beta (13.5-25 Hz) bands over time.

Tillman GD et al. Repetitive transcranial magnetic stimulation and threat memory: selective reduction of combat threat memory p300 response after right frontal-lobe stimulation. J Neuropsychiatry Clin Neurosci 23(1):40-7, 2011.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment in electroencephalography power in response to trauma-specific auditory stimuli
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences in change from baseline to 6 months following the 12-week interventions in change in electroencephalography (EEG) power within alpha- and theta-bands to trauma-specific threatening auditory stimuli compared to non-specific threatening and non-threatening auditory stimuli. For task conditions of interest, EEG power will be calculated separately at each electrode as log transformed, absolute power averages in the delta (1.5-3.5 Hz), theta (4-7.5 Hz), alpha (8-13 Hz), and beta (13.5-25 Hz) bands over time.

Tillman GD et al. Repetitive transcranial magnetic stimulation and threat memory: selective reduction of combat threat memory p300 response after right frontal-lobe stimulation. J Neuropsychiatry Clin Neurosci 23(1):40-7, 2011.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment in electroencephalography power in response to trauma-specific auditory stimuli
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences in change from baseline to 12 months following the 12-week interventions in change in electroencephalography (EEG) power within alpha- and theta-bands to trauma-specific threatening auditory stimuli compared to non-specific threatening and non-threatening auditory stimuli. For task conditions of interest, EEG power will be calculated separately at each electrode as log transformed, absolute power averages in the delta (1.5-3.5 Hz), theta (4-7.5 Hz), alpha (8-13 Hz), and beta (13.5-25 Hz) bands over time.

Tillman GD et al. Repetitive transcranial magnetic stimulation and threat memory: selective reduction of combat threat memory p300 response after right frontal-lobe stimulation. J Neuropsychiatry Clin Neurosci 23(1):40-7, 2011.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 1 month post-treatment in electroencephalography power in response to trauma-specific visual stimuli
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences in change from baseline to 1 month following the 12-week interventions in change in electroencephalography (EEG) power within alpha- and theta-bands to trauma-specific visual stimuli compared to non-specific threatening and non-threatening visual stimuli. For task conditions of interest, EEG power will be calculated separately at each electrode as log transformed, absolute power averages in the delta (1.5-3.5 Hz), theta (4-7.5 Hz), alpha (8-13 Hz), and beta (13.5-25 Hz) bands over time.

DeLaRosa BL et al. Electrophysiological spatiotemporal dynamics during implicit visual threat processing. Brain Cogn 91:54-61, 2014.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment in electroencephalography power in response to trauma-specific visual stimuli
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences in change from baseline to 6 months following the 12-week interventions in change in electroencephalography (EEG) power within alpha- and theta-bands to trauma-specific visual stimuli compared to non-specific threatening and non-threatening visual stimuli. For task conditions of interest, EEG power will be calculated separately at each electrode as log transformed, absolute power averages in the delta (1.5-3.5 Hz), theta (4-7.5 Hz), alpha (8-13 Hz), and beta (13.5-25 Hz) bands over time.

DeLaRosa BL et al. Electrophysiological spatiotemporal dynamics during implicit visual threat processing. Brain Cogn 91:54-61, 2014.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment in electroencephalography power in response to trauma-specific visual stimuli
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences in change from baseline to 12 months following the 12-week interventions in change in electroencephalography (EEG) power within alpha- and theta-bands to trauma-specific visual stimuli compared to non-specific threatening and non-threatening visual stimuli. For task conditions of interest, EEG power will be calculated separately at each electrode as log transformed, absolute power averages in the delta (1.5-3.5 Hz), theta (4-7.5 Hz), alpha (8-13 Hz), and beta (13.5-25 Hz) bands over time.

DeLaRosa BL et al. Electrophysiological spatiotemporal dynamics during implicit visual threat processing. Brain Cogn 91:54-61, 2014.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 1 month post-treatment in event-related potential responses in inhibitory control
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment

Evaluation of treatment group differences in change from baseline to 1 month following the 12-week interventions in change in event-related potential (ERP) on inhibitory control trials (i.e., No-Go trials on the semantically cued inhibitory control task). Measured as change in microvolts separately on the N2 and P3 ERP components.

Maguire MJ et al. The influence of perceptual and semantic categorization on inhibitory processing as measured by the N2-P3 response. Brain Cog 71; 196-203, 2009.

Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment in event-related potential responses in inhibitory control
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences in change from baseline to 6 months following the 12-week interventions in change in event-related potential (ERP) on inhibitory control trials (i.e., No-Go trials on the semantically cued inhibitory control task). Measured as change in microvolts separately on the N2 and P3 ERP components.

Maguire MJ et al. The influence of perceptual and semantic categorization on inhibitory processing as measured by the N2-P3 response. Brain Cog 71; 196-203, 2009.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12-month post-treatment in event-related potential responses in inhibitory control
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences in change from baseline to 12 months following the 12-week interventions in change in event-related potential (ERP) on inhibitory control trials (i.e., No-Go trials on the semantically cued inhibitory control task). Measured as change in microvolts separately on the N2 and P3 ERP components.

Maguire MJ et al. The influence of perceptual and semantic categorization on inhibitory processing as measured by the N2-P3 response. Brain Cog 71; 196-203, 2009.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 1-month post-treatment in resting-state electroencephalography power
Time Frame: Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Evaluation of treatment group differences in change from baseline to 1 month following the 12-week interventions in change in resting-state electroencephalography (EEG) power. EEG power will be calculated separately at each electrode as the log transformed, absolute power in the delta (1.5-3.5 Hz), theta (4-7.5 Hz), alpha (8-13 Hz), and beta (13.5-25 Hz) bands for each eyes-open and eyes-closed epoch, and groups differences from baseline to 1-month in the average differences in the log transformed, absolute power between the eyes-open and eyes-closed conditions will be evaluated.
Outcome measures will be measured twice over a period of 17 weeks: Baseline, 1-Month Post-Treatment
Treatment group differences in change from baseline to 6-months post-treatment in resting-state electroencephalography power
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Evaluation of treatment group differences in change from baseline to 6 months following the 12-week interventions in change in resting-state electroencephalography (EEG) power. EEG power will be calculated separately at each electrode as the log transformed, absolute power in the delta (1.5-3.5 Hz), theta (4-7.5 Hz), alpha (8-13 Hz), and beta (13.5-25 Hz) bands for each eyes-open and eyes-closed epoch, and groups differences from baseline to 1-month in the average differences in the log transformed, absolute power between the eyes-open and eyes-closed conditions will be evaluated.
Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12-months post-treatment in resting-state electroencephalography power
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Evaluation of treatment group differences in change from baseline to 12 months following the 12-week interventions in change in resting-state electroencephalography (EEG) power. EEG power will be calculated separately at each electrode as the log transformed, absolute power in the delta (1.5-3.5 Hz), theta (4-7.5 Hz), alpha (8-13 Hz), and beta (13.5-25 Hz) bands for each eyes-open and eyes-closed epoch, and groups differences from baseline to 1-month in the average differences in the log transformed, absolute power between the eyes-open and eyes-closed conditions will be evaluated.
Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 6-months post-treatment trauma-specific responses in blood oxygen level dependent functional magnetic resonance imaging
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment

Evaluation of treatment group differences from baseline to 6 months following the 12-week interventions in functional magnetic resonance imaging (fMRI) blood oxygen level dependent (BOLD) signal change (mean percent signal-change from the task baseline) to trauma-specific visual stimuli compared to non-specific threatening and non-threatening visual stimuli.

Calley CS, et al. Threat as a feature in visual semantic object memory. Hum Brain Mapp. 34(8):1946-55, 2013.

Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment trauma-specific responses in blood oxygen level dependent functional magnetic resonance imaging
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Evaluation of treatment group differences from baseline to 12 months following the 12-week interventions in functional magnetic resonance imaging (fMRI) blood oxygen level dependent (BOLD) signal change (mean percent signal-change from the task baseline) to trauma-specific visual stimuli compared to non-specific threatening and non-threatening visual stimuli.

Calley CS, et al. Threat as a feature in visual semantic object memory. Hum Brain Mapp. 34(8):1946-55, 2013.

Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Treatment group differences in change from baseline to 6 months post-treatment in resting-state functional connectivity
Time Frame: Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Evaluation of treatment group differences from baseline to 6 months following the 12-week interventions in functional magnetic resonance imaging (fMRI) blood oxygen level dependent (BOLD) resting-state connectivity. Group differences in seed-based connectivity indices (mean standardized coherence parameter estimates) with right dorsolateral prefrontal cortex, amygdalae, thalamus, and dorsal anterior cingulate as the primary therapeutic targets will be calculated.
Outcome measures will be measured twice over a period of 37 weeks: Baseline, 6-Month Post-Treatment
Treatment group differences in change from baseline to 12 months post-treatment in resting-state functional connectivity
Time Frame: Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment
Evaluation of treatment group differences from baseline to 12 months following the 12-week interventions in functional magnetic resonance imaging (fMRI) blood oxygen level dependent (BOLD) resting-state connectivity. Group differences in seed-based connectivity indices (mean standardized coherence parameter estimates) with right dorsolateral prefrontal cortex, amygdalae, thalamus, and dorsal anterior cingulate as the primary therapeutic targets will be calculated.
Outcome measures will be measured twice over a period of 61 weeks: Baseline, 12-Month Post-Treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: John Hart, Jr., MD, The University of Texas at Dallas
  • Principal Investigator: F. Andrew Kozel, MD, Florida State University, College of Medicine
  • Principal Investigator: John Burruss, MD, Metrocare Services of Dallas

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2019

Primary Completion (Estimated)

July 31, 2024

Study Completion (Estimated)

July 31, 2024

Study Registration Dates

First Submitted

April 4, 2019

First Submitted That Met QC Criteria

April 26, 2019

First Posted (Actual)

May 1, 2019

Study Record Updates

Last Update Posted (Actual)

January 22, 2024

Last Update Submitted That Met QC Criteria

January 18, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post Traumatic Stress Disorder

Clinical Trials on Active rTMS

3
Subscribe